Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)

Nardin, Charlée; Hennemann, Aymeric; Diallo, Kadiatou; Funck‐Brentano, Elisa; Puzenat, E.; Heidelberger, Valentine; Jeudy, G.; Samimi, M.; Lesage, C.; Boussemart, Lise; Peuvrel, L.; Rouanet, Jacques; Brunet‐Possenti, F.; Gérard, E.; Seris, Alice; Jouary, Thomas; Saint‐Jean, M.; Puyraveau, Marc; Saïag, Philippe; Aubin, F.

doi:10.3390/cancers15143564

Public

Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)

Published in Cancers • Jul 10, 2023

Authors:

Charlée Nardin

Aymeric Hennemann

Kadiatou Diallo

Abstract

Background: The long-term effectiveness of immune checkpoint inhibitor (ICI) rechallenge for progressive or recurrent advanced melanoma following previous disease control induced by ICI has not been thoroughly described in the literature. Patients and methods: In this retrospective multicenter natio...

Subject

Medicine

Ipilimumab

Nivolumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!